Cargando…

Canadian regulatory perspectives on genome engineered crops

New breeding techniques in plant agriculture exploded upon the scene about two years ago, in 2014. While these innovative plant breeding techniques, soon to be led by CRISPR/Cas9, initially appear to hold tremendous promise for plant breeding, if not a revolution for the industry, the question of ho...

Descripción completa

Detalles Bibliográficos
Autor principal: Smyth, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592975/
https://www.ncbi.nlm.nih.gov/pubmed/27858499
http://dx.doi.org/10.1080/21645698.2016.1257468
_version_ 1783262970833272832
author Smyth, Stuart J.
author_facet Smyth, Stuart J.
author_sort Smyth, Stuart J.
collection PubMed
description New breeding techniques in plant agriculture exploded upon the scene about two years ago, in 2014. While these innovative plant breeding techniques, soon to be led by CRISPR/Cas9, initially appear to hold tremendous promise for plant breeding, if not a revolution for the industry, the question of how the products of these technologies will be regulated is rapidly becoming a key aspect of the technology's future potential. Regulation of innovative technologies and products has always lagged that of the science, but in the past decade, regulatory systems in many jurisdictions have become gridlocked as they try to regulate genetically modified (GM) crops. This regulatory incapability to efficiently assess and approve innovative new agricultural products is particularly important for new plant breeding techniques as if these techniques are classified as genetically modified breeding techniques, then their acceptance and future will diminish considerably as they will be rejected by the European Union. Conversely, if the techniques are accepted as conventional plant breeding, then the future is blindingly bright. This article examines the international debate about the regulation of new plant breeding techniques and then assesses how the Canadian regulatory system has approached the regulation of these technologies through two more public product approvals, GM apples and GM potatoes, then discusses other crop variety approval and those in the regulatory pipeline.
format Online
Article
Text
id pubmed-5592975
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-55929752017-11-18 Canadian regulatory perspectives on genome engineered crops Smyth, Stuart J. GM Crops Food Research Papers New breeding techniques in plant agriculture exploded upon the scene about two years ago, in 2014. While these innovative plant breeding techniques, soon to be led by CRISPR/Cas9, initially appear to hold tremendous promise for plant breeding, if not a revolution for the industry, the question of how the products of these technologies will be regulated is rapidly becoming a key aspect of the technology's future potential. Regulation of innovative technologies and products has always lagged that of the science, but in the past decade, regulatory systems in many jurisdictions have become gridlocked as they try to regulate genetically modified (GM) crops. This regulatory incapability to efficiently assess and approve innovative new agricultural products is particularly important for new plant breeding techniques as if these techniques are classified as genetically modified breeding techniques, then their acceptance and future will diminish considerably as they will be rejected by the European Union. Conversely, if the techniques are accepted as conventional plant breeding, then the future is blindingly bright. This article examines the international debate about the regulation of new plant breeding techniques and then assesses how the Canadian regulatory system has approached the regulation of these technologies through two more public product approvals, GM apples and GM potatoes, then discusses other crop variety approval and those in the regulatory pipeline. Taylor & Francis 2016-11-18 /pmc/articles/PMC5592975/ /pubmed/27858499 http://dx.doi.org/10.1080/21645698.2016.1257468 Text en © 2017 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Research Papers
Smyth, Stuart J.
Canadian regulatory perspectives on genome engineered crops
title Canadian regulatory perspectives on genome engineered crops
title_full Canadian regulatory perspectives on genome engineered crops
title_fullStr Canadian regulatory perspectives on genome engineered crops
title_full_unstemmed Canadian regulatory perspectives on genome engineered crops
title_short Canadian regulatory perspectives on genome engineered crops
title_sort canadian regulatory perspectives on genome engineered crops
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592975/
https://www.ncbi.nlm.nih.gov/pubmed/27858499
http://dx.doi.org/10.1080/21645698.2016.1257468
work_keys_str_mv AT smythstuartj canadianregulatoryperspectivesongenomeengineeredcrops